Giriş ve Amaç: Sirozlu hastalarda hepatosellüler karsinom görülmesikliginin artmasinin yaninda bazi karaciger dışı kanserlerin görülmesikligi da artmaktadır. Bizim merkezimizde transplantasyon öncesi takipedilen karaciger sirozlu hastalarda karaciger dışı kanserlerin artip artmadigini değerlendirdik. Gereç ve Yöntem: Bu retrospektif çalışmada merkezimizde takip edilen 1017 sirozlu hastadan karaciger dışıkanser gelisen 37 hastanın verileri değerlendirildi ve kanser insidansoranlari belirlendi. Bu veriler hastanemize ait kanser insidans oranlariile karsilastirildi. Bulgular: Karaciger dışı kanserlerin görülme sikligikontrol grubuna göre erkeklerde 4 kat, kadınlarda 9 kat, toplamda ise7,5 kat artmis idi (p <0,05). Sirozlu hastalarda kanser türlerine görekıyaslandiginda ise lösemilerde 93 kat, lenfomalarda 33 kat, safrakesesi kanserlerinde 31 kat, mide kanserlerinde 15,5 kat, renal hücrelikanserlerde 12 kat, sarkomlarda 10 kat, mesane kanserlerinde 9 kat,pankreas, larinks, endometrium ve akciger kanserlerinde yaklasik 6kat, prostat kanserlerinde 4 kat (p <0,05), kolon kanserlerinde 2,5 kat,meme kanserlerinde ise 1,2 kat artis söz konusu idi (p >0,05). Sonuç:Sonuç olarak sirozlu hastalarda basta lenfoma ve lösemi olmak üzerebütün karaciger dışı kanserlerin görülme sikligi önemli oranda artmisolarak bulundu.
Background and Aims: Besides the incidence of hepatocellular carcinoma, the incidence of some non-hepatic cancers also increases in patients with cirrhosis. We evaluated whether there was an increase in the incidence of non-hepatic cancers in patients with cirrhosis diagnosed before transplantation in our center. Materials and Methods: In this retrospective study, a total sample of 1017 patients with cirrhosis who were followed up at our center was reviewed, of which the data of 37 patients who did not develop non-hepatic cancer were evaluated, and the incidence of cancer was determined. These data were compared with the incidence rate of cancer at our hospital. Results: The incidence of non-hepatic cancers was found to be increased by 4-fold in males and by 9-fold in females (overall 7.5-fold) among patients with cirrhosis compared with that in the control group (p < 0.05). Comparison based on the type of cancers in cirrhotic patients revealed an increase by 93-fold for leukemia, 33-fold for lymphoma, 31-fold for gallbladder cancers, 15.5-fold for gastric cancers, 12-fold for renal cell cancers, 10-fold for sarcomas, 9-fold for urinary bladder cancers, ~6- fold for pancreatic, laryngeal, endometrial, and lung cancers, 4-fold for prostate cancers (p < 0.05), 2.5-fold for colon cancers, and 1.2-fold for breast cancers (p > 0.05). Conclusion: There was an increase in the incidence of all non-hepatic cancers, primarily lymphoma and leukemia, in patients with cirrhosis.